

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Mohamed Aagab asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on May 7, 2023, at the BMO Vancouver Marathon, in Vancouver, BC.
2. Mohamed Aagab (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Recombinant Erythropoietin (rEPO), a Prohibited Substance.
3. Following receipt of the CCES’s Notice of Charge asserting an anti-doping rule violation (ADRV) for the presence and Use of the Prohibited Substance, the Athlete signed an Early Admission and Acceptance of Sanction Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
5. As Canada’s National Anti-Doping Organization, the CCES is in compliance with the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of and participates in the activities of Athletics Canada. According to CADP Rule 1.3, the CADP provisions apply to all members of, and Participants in activities of Sport Organizations adopting it. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. Athletics Canada adopted the CADP on October 29, 2020. Therefore, as a Participant in Athletics Canada activities, the Athlete is subject to the CADP.

Doping Control

7. On May 7, 2023, the CCES conducted an In-Competition Sample collection session at the BMO Vancouver Marathon in Vancouver, BC. Testing was conducted on athletes as part of

the CCES's additional testing services requested by Athletics Canada, all pursuant to the CADP.

8. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 7089290.
9. On May 9, 2023, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, QC.

Results Management

10. The AAF was reported by the INRS on July 19, 2023. The Certificate of Analysis indicated the presence of recombinant EPO (rEPO).
11. Recombinant EPO is classified as a Prohibited Substance on WADA's 2023 Prohibited List.
12. The CCES commenced an initial review into the Athlete's AAF and issued a notification of a potential ADRV on August 10, 2023.
13. In response to the CCES's Notification letter on August 13, 2023, the Athlete provided an explanation for his AAF to the CCES.
14. On September 12, 2023, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of the Prohibited Substance.
15. In accordance with CADP Rule 10.2.1.1, the sanction for an ADRV involving the presence and Use of Prohibited Substances is a four (4) year period of Ineligibility. The CCES asserted a four (4) year sanction within its Notice of Charge of September 12, 2023.

Confirmation of Violation and Sanction

16. In accordance with CADP Rule 10.8.1, the CCES informed the Athlete on September 12, 2023, that should the Athlete exercise their option to sign the Early Admission and Acceptance of Sanction Form, the Athlete would receive a one (1) year reduction of the four (4) year period of Ineligibility asserted by the CCES.
17. On October 3, 2023¹, the Athlete signed and submitted the Early Admission and Acceptance of Sanction Form to the CCES. Accordingly, effective October 3, 2023, an ADRV has been confirmed against the Athlete for the presence and Use of the identified Prohibited Substance. In accordance with CADP Rules 7.4.1, 10.2.1, 10.8.1 and 10.13.2.1, the sanction for this violation is a three (3) year period of Ineligibility which commenced on September 12, 2023, the date the Athlete was Provisionally Suspended, and concludes on September

¹ The CCES notes that the 20-day deadline indicated in Rule 10.8.1 of the CADP would have expired on October 2, 2023; however, since October 2, 2023 was a federal holiday in Canada, the CCES extended the Athlete's deadline to sign the Early Acceptance of Sanction and Admission Form to October 3, 2023.

11, 2026. Further, in accordance with CADP Rule 10.10, any competitive results obtained by the Athlete, from date of Sample collection, shall be Disqualified.

18. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 2nd day of November 2023.



Kevin Bean
Executive Director, Sport Integrity
CCES